Stocks of the Hour: NeuroScientific Biopharmaceuticals, Lithium Plus Minerals & Bluglass

Company News

by Lauren Evans

NeuroScientific Biopharmaceuticals (ASX:NSB) has announced positive preliminary results of its drug candidate EmtinB™ in a gold standard animal model of multiple sclerosis. The study was conducted to replicate the inflammatory mechanisms of human MS, and demonstrate a therapeutic treatment response. The study was undertaken by contract research partner Biospective, Canada. Shares are trading 20 per cent higher at $0.21.

Lithium Plus Minerals’ (ASX:LPM) mining management plan for its Bynoe Lithium project has been approved by the Northern Territory Department. The Darwin-based drilling contractor GeoDrilling is scheduled to mobilise in the coming weeks, while site preparation works have already commenced. Shares are trading 40.7 per cent higher at $0.42.

Semiconductor developer BluGlass (ASX:BLG) has shipped its first laser prototypes to its initial customer in order to gain customer feedback. Executive chairman James Walker said, “this is an important commercialisation milestone for BluGlass, with our first alpha laser diode products being shipped to our first end customer.” Shares are trading 15.4 per cent higher at 3 cents.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.